Genetics of familial melanoma: 20 years after CDKN 2 A
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Summary: Twenty years ago, the first familial melanoma susceptibility gene, CDKN 2A, was identified. Two years later, another high‐penetrance gene, CDK 4, was found to be responsible for melanoma development in some families. Progress in identifying new familial melanoma genes was subsequently slow; however, with the advent of next‐generation sequencing, a small number of new high‐penetrance genes have recently been uncovered. This approach has identified the lineage‐specific oncogene MITF as a susceptibility gene both in melanoma families and in the general population, as well as the discovery of telomere maintenance as a key pathway underlying melanoma predisposition. Given these rapid recent advances, this approach seems likely to continue to pay dividends. Here, we review the currently known familial melanoma genes, providing evidence that most additionally confer risk to other cancers, indicating that they are likely general tumour suppressor genes or oncogenes, which has significant implications for surveillance and screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shelterin: the protein complex that shapes and safeguards human telomeres
de Lange, T. (2005) · Genes & Development · doi:10.1101/gad.1346005 · Cited by 3,056 · cited 1×
“Collectively, they are necessary for all telomere functions, which include the protection of telomeres from degradation or aberrant recombination, as well as from being inappropriately processed by the DNA-repair pathway (De Lange, 2005).”
TERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799 · cited 5×
“Horn and colleagues (Horn et al., 2013) analysed tumours derived from sporadic CMM cases and found that 85% of metastatic tumours and 33% of primary tumours carried somatic mutations in the promoter of TERT, with the majority of these mutations occurring at two hotspots (at positions 124 bp and 146…”
BackgroundInfluentialZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548 · cited 2×
“In a separate study, MITF was shown to be amplified in 10% of primary CMM, 21% of metastatic tumours and not amplified in benign naevi, suggestive of MITF being a lineage-specific oncogene (Garraway et al., 2005).”
BackgroundKillela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368
Germline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076
Mammalian Telomeres Resemble Fragile Sites and Require TRF1 for Efficient Replication
Sfeir, A., Kosiyatrakul, S. T., Hockemeyer, D., MacRae, S. L., Karlseder, J., Schildkraut, C. L., & de Lange, T. (2009) · Cell · doi:10.1016/j.cell.2009.06.021 · Cited by 990
The p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Frequency of TERT promoter mutations in human cancers
Vinagre, J., Almeida, A., Pópulo, H., Batista, R., Lyra, J., Pinto, V., Coelho, R., Celestino, R., Prazeres, H., Lima, L., et al. (2013) · Nature Communications · doi:10.1038/ncomms3185 · Cited by 898
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818 · cited 18×
“Mutations in CDK4, MITF, BAP1, TERT, POT1, ACD, TERF2IP are rare, with each contributing to 1% of all familial clustering of melanoma.”
BackgroundInfluentialSelf-citationThe POT1-TPP1 telomere complex is a telomerase processivity factor.
Wang, F., Podell, E. R., Zaug, A. J., Yang, Y., Baciu, P., Cech, T. R., & Lei, M. (2007) · Nature · doi:10.1038/nature05454 · Cited by 704
Ye, J. Z.-S., Hockemeyer, D., Krutchinsky, A. N., Loayza, D., Hooper, S. M., Chait, B. T., & de Lange, T. (2004) · Genes & Development · doi:10.1101/gad.1215404 · Cited by 459
PTOP interacts with POT1 and regulates its localization to telomeres
Liu, D., Safari, A., O'Connor, M. S., Chan, D. W., Laegeler, A., Qin, J., & Songyang, Z. (2004) · Nature Cell Biology · doi:10.1038/ncb1142 · Cited by 450
POT1 loss-of-function variants predispose to familial melanoma
Robles-Espinoza, C. D., Harland, M., Ramsay, A. J., Aoude, L. G., Quesada, V., Ding, Z., Pooley, K. A., Pritchard, A. L., Tiffen, J. C., Petljak, M., et al. (2014) · Nature Genetics · doi:10.1038/ng.2947 · Cited by 391 · cited 2×
“Exome sequencing was recently used to identify loss-of-function mutations in POT1 in high-density CMM families from Australia, The UK and The Netherlands (Robles-Espinoza et al., 2014).”
BackgroundSelf-citationBorg, A., Sandberg, T., Nilsson, K., Johannsson, O., Klinker, M., Masback, A., Westerdahl, J., Olsson, H., & Ingvar, C. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1260 · Cited by 345 · cited 1×
“Many other studies have since identified an increased occurrence of pancreatic cancer in CDKN2A mutationpositive melanoma families (Borg et al., 1996, 2000; Ciotti et al., 1996; Ghiorzo et al., 1999; Goldstein et al., 2000; Gruis et al., 1995; Lal et al., 2000a,b; Liu et al., 1999; Lynch et al.,…”
BackgroundRare missense variants in POT1 predispose to familial cutaneous malignant melanoma
NCI DCEG Cancer Sequencing Working Group, Shi, J., Laboratory, N. D. C. G. R., French Familial Melanoma Study Group, Yang, X. R., Ballew, B., Rotunno, M., Calista, D., Fargnoli, M. C., Ghiorzo, P., et al. (2014) · Nature Genetics · doi:10.1038/ng.2941 · Cited by 331
The CDKN2A (p16) Gene and Human Cancer
Foulkes, W. D., Flanders, T. Y., Pollock, P. M., & Hayward, N. K. (1997) · Molecular Medicine · doi:10.1007/bf03401664 · Cited by 292
Self-citationGermline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma
Xu, J., Kadariya, Y., Cheung, M., Pei, J., Talarchek, J., Sementino, E., Tan, Y., Menges, C. W., Cai, K. Q., Litwin, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1328 · Cited by 144 · cited 2×
“…to asbestos, Xu and colleagues demonstrated that tumour and normal mesothelial cells from these mice had decreased expression of the Rb1 tumour suppressor mRNA, phosphorylated protein and total protein, due to hypermethylation of the Rb1 promoter compared to wildtype mice (Xu et al., 2014).”
Background
Cited by
An ongoing role for Wnt signaling in differentiating melanocytes in vivo
Vibert, L., Aquino, G., Gehring, I., Subkankulova, T., Schilling, T. F., Rocco, A., & Kelsh, R. N. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12568 · Cited by 35
“…melanocyte development are of major interest from developmental and stem cell biology and applied biology perspectives, with clear relevance to understanding human pigmentary disease (Aoude et al., 2015; Mort et al., 2015; Speeckaert et al., 2015; White et al., 2011; Yamaguchi and Hearing, 2014).”
BackgroundPrecision Prevention: The Current State and Future of Genomically Guided Cancer Prevention
Kassem, N., Stout, L. A., Hunter, C., Schneider, B., & Radovich, M. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00278 · Cited by 5
Metadata
- Authors
- Aoude, L. G., Wadt, K. A. W., Pritchard, A. L., & Hayward, N. K.
- Venue
- Pigment Cell & Melanoma Research
- Publisher
- Wiley
- Published
- 2015-01-05
- Volume
- 28
- Issue
- 2
- Pages
- 148-160
- ISSN
- 1755-1471 (ISSN-L)
- 1755-148X
- OpenAlex
- W1968003842
- Cited by
- 164
- References
- 18
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.